Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.47 |
| ▸ | KDR | P35968 | 8/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.44 |
| ▸ | FLT4 | P35916 | 3/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3750220 | 0.92 | KDR (0.47) | METKDRPDGFRBFLT4FLT3 | |
| SCHEMBL7783938 | 0.85 | KDR (0.59) | METKDRPDGFRBFLT4 | |
| SCHEMBL3758006 | 0.83 | HDAC1 (0.46) | METKDRHDAC2PDGFRA | |
| SCHEMBL7783999 | 0.78 | KDR (0.62) | METKDRPDGFRBFLT4HDAC2 | |
| SCHEMBL3755654 | 0.77 | KDR (0.61) | METKDRPDGFRBFLT4FLT3 | |
| SCHEMBL3752578 | 0.76 | PDGFRA (0.57) | METKDRADORA2AHDAC3HDAC2 | |
| SCHEMBL3750231 | 0.72 | KDR (0.68) | METKDRPDGFRA | |
| SCHEMBL3754551 | 0.70 | KDR (0.64) | METKDRPDGFRBFLT4FLT3 | |
| SCHEMBL3758508 | 0.69 | KDR (0.65) | METKDRPDGFRBFLT4FLT3 | |
| SCHEMBL3753142 | 0.69 | KDR (0.62) | METKDRPDGFRBFLT4FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211901-B2 | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2012-07-03 | — | — | US | disclosed |
| US-20100298358-A1 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298358-A1 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC5 | MET 2038/4885KDR 2729/4885PDGFRB 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.